-
EP3877056
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3877056
| EP3877056 - TEPOXALIN TARGETING OF ABCB1 OVEREXPRESSING CANCERS [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 13.08.2021 Database last updated on 19.10.2024 | |
| Former | The international publication has been made Status updated on 16.05.2020 | Most recent event Tooltip | 08.12.2023 | Change - representative | Applicant(s) | For all designated states The Broad Institute, Inc. 415 Main Street Cambridge, MA 02142 / US | For all designated states Dana Farber Cancer Institute, Inc. 450 Brookline Avenue Boston, Massachusetts 02215 / US | For all designated states Instituto Carlos Slim de la Salud, A.C. Lago Zurich 245 Plaza Carso, Edificio Presa Falcon piso 20 Colonia Granada Ampliacion C.P. 11529 Mexico, D.F., Mexico / MX | [2021/37] | Inventor(s) | 01 /
CORSELLO, Steven c/o DANA-FARBER CANCER INSTITUTE, INC. 450 Brookline Ave Boston, Massachusetts 02215 / US | 02 /
SPANGLER, Ryan c/o THE BROAD INSTITUTE, INC. 415 Main Street Cambridge, Massachusetts 02142 / US | 03 /
NAGARI, Rohith c/o THE BROAD INSTITUTE, INC. 415 Main Street Cambridge, Massachusetts 02142 / US | 04 /
GOLUB, Todd c/o THE BROAD INSTITUTE, INC. 415 Main Street Cambridge, Massachusetts 02142 / US | [2021/37] | Representative(s) | Maschio & Soames IP Ltd 30 Carlton Crescent Southampton SO15 2EW / GB | [N/P] |
| Former [2021/37] | Maschio, Antonio Maschio & Soames IP Limited 30 Carlton Crescent Southampton SO15 2EW / GB | Application number, filing date | 19881043.4 | 08.11.2019 | [2021/37] | WO2019US60516 | Priority number, date | US201862758294P | 09.11.2018 Original published format: US 201862758294 P | [2021/37] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2020097492 | Date: | 14.05.2020 | Language: | EN | [2020/20] | Type: | A1 Application with search report | No.: | EP3877056 | Date: | 15.09.2021 | Language: | EN | The application published by WIPO in one of the EPO official languages on 14.05.2020 takes the place of the publication of the European patent application. | [2021/37] | Search report(s) | International search report - published on: | US | 14.05.2020 | (Supplementary) European search report - dispatched on: | EP | 15.07.2022 | Classification | IPC: | A61P35/00, G01N33/48, G01N33/50, G01N33/53 | [2021/37] | CPC: |
G01N33/6872 (EP);
G01N33/57492 (EP,US);
A61K31/415 (US);
A61K45/06 (US);
A61P35/00 (EP,US);
C12Q1/6886 (EP,US);
C12Q2600/106 (EP,US);
C12Q2600/158 (EP,US);
G01N2333/70596 (EP,US);
G01N2800/52 (EP)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/37] | Title | German: | TEPOXALIN-ZIELE VON ABCB1-ÜBEREXPRIMIERENDEN KREBSARTEN | [2021/37] | English: | TEPOXALIN TARGETING OF ABCB1 OVEREXPRESSING CANCERS | [2021/37] | French: | CIBLAGE DE TÉPOXALINE POUR CANCERS SUREXPRIMANT ABCB1 | [2021/37] | Entry into regional phase | 18.06.2021 | National basic fee paid | 18.06.2021 | Search fee paid | 18.06.2021 | Designation fee(s) paid | 18.06.2021 | Examination fee paid | Examination procedure | 18.06.2021 | Examination requested [2021/37] | 07.02.2023 | Amendment by applicant (claims and/or description) | Request for further processing for: | The application is deemed to be withdrawn due to non-payment of the search fee | 18.06.2021 | Request for further processing filed | 18.06.2021 | Full payment received (date of receipt of payment) Request granted | 02.07.2021 | Decision despatched | The application is deemed to be withdrawn due to non-payment of the filing fee | 18.06.2021 | Request for further processing filed | 18.06.2021 | Full payment received (date of receipt of payment) Request granted | 02.07.2021 | Decision despatched | The application is deemed to be withdrawn due to non-payment of the examination fee | 18.06.2021 | Request for further processing filed | 18.06.2021 | Full payment received (date of receipt of payment) Request granted | 02.07.2021 | Decision despatched | 18.06.2021 | Request for further processing filed | 18.06.2021 | Full payment received (date of receipt of payment) Request granted | 02.07.2021 | Decision despatched | The application is deemed to be withdrawn due to non-payment of designation fees TR, SM, SK, SI, SE, RS, RO, PT, PL, NO, NL, MT, MK, MC, LV, LU, LT, IT, IS, IE, HU, HR, GR, GB, FR, FI, ES, EE, DK, DE, CZ, CY, CH, BG, BE, AT, AL | 18.06.2021 | Request for further processing filed | 18.06.2021 | Full payment received (date of receipt of payment) Request granted | 02.07.2021 | Decision despatched | Fees paid | Renewal fee | 29.11.2021 | Renewal fee patent year 03 | 28.11.2022 | Renewal fee patent year 04 | 27.11.2023 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [XI] - JOSEPH SOTTNIK, "The Role of Innate Immunity and Angiogenesis in Osteosarcoma Growth and Metastasis", DOCTORAL DISSERTATION, COLORADO STATE UNIVERSITY, (2010), pages 1 - 286, XP055705798 [X] 6,9,11 * Chapter 3 * [I] 7,8,12-15 | [X] - REED K ET AL, "The temporal relationship between ABCB1 promoter hypomethylation, ABCB1 expression and acquisition of drug resistance", THE PHARMACOGENOMICS JOURNAL, NATURE PUBLISHING GROUP, GB, vol. 10, no. 6, doi:10.1038/TPJ.2010.1, ISSN 1470-269X, (20100202), pages 489 - 504, (20100202), XP037747288 [X] 11 * page 491, column 1, paragraph 2 - column 2, paragraph 2 * DOI: http://dx.doi.org/10.1038/tpj.2010.1 | [I] - LOFTUS J. P. ET AL, "The 5-lipoxygenase inhibitor tepoxalin induces oxidative damage and altered PTEN status prior to apoptosis in canine osteosarcoma cell lines : 5-lipoxygenase inhibition in osteosarcoma", VETERINARY AND COMPARATIVE ONCOLOGY, (20140512), vol. 14, no. 2, doi:10.1111/vco.12094, ISSN 1476-5810, pages e17 - e30, XP055938670 [I] 6-9,11-15 * abstract * DOI: http://dx.doi.org/10.1111/vco.12094 | [I] - WAKSHLAG JOSEPH J. ET AL, "5-Lipoxygenase expression and tepoxalin-induced cell death in squamous cell carcinomas in cats", AMERICAN JOURNAL OF VETERINARY RESEARCH, US, (20111001), vol. 72, no. 10, doi:10.2460/ajvr.72.10.1369, ISSN 0002-9645, pages 1369 - 1377, XP055938675 [I] 6-9,11-15 * abstract * DOI: http://dx.doi.org/10.2460/ajvr.72.10.1369 | [A] - WUNCHANA SEUBWAIET AL, "5-Lipoxygenase expression and tepoxalin-induced cell death in squamous cell carcinomas in cats", ONCOLOGY RESEARCH., US, (20160121), vol. 23, doi:10.3727/096504015X14424348426071, ISSN 0965-0407, pages 21 - 28, XP055705803 [A] 1-15 * the whole document * DOI: http://dx.doi.org/10.3727/096504015X14424348426071 | [IP] - Steven M. Corsello ET AL, "Non-oncology drugs are a source of previously unappreciated anti-cancer activity", bioRxiv, doi:10.1101/730119, (20190809), URL: https://www.biorxiv.org/content/10.1101/730119v1.full.pdf, XP055708552 [IP] 1-15 * page 6, paragraph 3 - page 7, paragraph 2; figure 6 * DOI: http://dx.doi.org/10.1101/730119 | [XPI] - Lu Xinyang ET AL, "Original Article Tepoxalin a dual 5-LOX-COX inhibitor and erlotinib an EGFR inhibitor halts progression of gastric cancer in tumor xenograft mice", Am J Transl Res, (20181130), URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291731/pdf/ajtr0010-3847.pdf, (20220705), XP055938693 [XP] 6,7,9 * abstract * [I] 8,11-15 | [T] - CORSELLO STEVEN M. ET AL, "Discovering the anticancer potential of non-oncology drugs by systematic viability profiling", NATURE CANCER, vol. 1, no. 2, doi:10.1038/s43018-019-0018-6, (20200120), pages 235 - 248, URL: https://www.nature.com/articles/s43018-019-0018-6.pdf, XP055938662 [T] * abstract * * page 240, column 2, paragraph 2 - page 243, column 1, paragraph 2; figure 7 * DOI: http://dx.doi.org/10.1038/s43018-019-0018-6 | [T] - MCQUERRY JASMINE A. ET AL, "Tepoxalin increases chemotherapy efficacy in drug-resistant breast cancer cells overexpressing the multidrug transporter gene ABCB1", TRANSLATIONAL ONCOLOGY, United States, (20210720), vol. 14, no. 10, doi:10.1016/j.tranon.2021.101181, ISSN 1936-5233, page 101181, XP055938648 [T] * the whole document * DOI: http://dx.doi.org/10.1016/j.tranon.2021.101181 | International search | [Y]US2010196907 (SEMIZAROV DIMITRI [US], et al) [Y] 1-4, 10-14, 16/14* ; abstract; para [0002], [0171] *; | [Y] - SEUBWAI et al, "Inhibition of NF-kB Activity Enhances Sensitivity to Anticancer Drugs in Cholangiocarcinoma Cells", Oncology Research, (20160000), vol. 23, doi:10.3727/096504015X14424348426071, ISSN 0965-0407, pages 21 - 28, XP055705803 [Y] 1-4, 10-16 * , pp 21-28; abstract; pg 24, col 1, para 4; pg 26, col 1, para 1 * DOI: http://dx.doi.org/10.3727/096504015X14424348426071 | [Y] - Sottnik Joseph, "The Role of Innate Immunity and Angiogenesis in Osteosarcoma Growth and Metastasis", Graduate Degree Program Paper, (20100101), pages 1 - 286, XP055705798 [Y] 1-4, 10-16 * , para 3 * |